Open AccessEffectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
Author(s) -
Seong Jin Choi,
Sang-Won Park,
Eunyoung Lee
Publication year - 2022
Publication title -
infection and chemotherapy/gam'yeom gwa hwahag yo'beob/infection and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.724
H-Index - 26
eISSN - 2092-6448
pISSN - 1598-8112
DOI - 10.3947/ic.2021.0140
Subject(s) - medicine , odds ratio , confidence interval , oxygen therapy , pneumonia , retrospective cohort study , logistic regression , covid-19 , subgroup analysis , cohort , disease , infectious disease (medical specialty)
Monoclonal antibodies are a treatment option for patients with mild-to-moderate coronavirus disease (COVID-19). We investigated the effectiveness of regdanvimab, an anti-severe acute respiratory syndrome coronavirus-2 monoclonal antibody approved in Korea, in the treatment of patients with mild-to-moderate COVID-19.